Q-Line Biotech Ltd. is stepping into the public markets with a maiden book-building issue to raise Rs. 214.48 crore at the upper price band. Operating in the in-vitro diagnostics sector since 2013, the company manufactures and markets medical reagents, point-of-care devices, consumables, and diagnostic equipment. Its operations span major segments like clinical chemistry, haematology, immunodiagnostics, and molecular diagnostics. During the pandemic, it also added Covid testing kits such as RT-PCR and RNA extraction kits to its roster through internal R&D and third-party collaborations.
The company maintains a research-focused setup, employing 19 personnel in its R&D laboratories as of March 31, 2026, alongside a total permanent payroll of 362 employees and 223 contract workers. Its products target hospitals, medical colleges, and independent diagnostic service providers across the country.
Issue Structure and Capital Deployment
The IPO consists of 6,253,200 equity shares with a face value of Rs. 10 each, offered within a price band of Rs. 326 to Rs. 343 per share. Investors must bid for a minimum lot size of 800 shares, requiring a capital outlay of Rs. 274,400 at the upper end of the band. Subsequent bids must be in multiples of 400 shares. This offering represents 26.81% of the post-issue paid-up capital of the firm, and the shares are slated to list on the NSE SME Emerge platform.
The net proceeds from the fresh issue are earmarked for specific corporate needs: Rs. 93.50 crore will support working capital requirements, Rs. 90.00 crore will go toward paying off or pre-paying select borrowings, and the remainder will support general corporate purposes. Ahead of the public opening, the company secured Rs. 27.44 crore through a pre-IPO placement of 800,000 shares at Rs. 343 each in May 2026. At the upper price band, the total market capitalization of the firm will reach Rs. 800.16 crore, pushing its paid-up equity capital from Rs. 17.07 crore up to Rs. 23.33 crore.
The issue is jointly managed by Hem Securities Ltd. and Share India Capital Services Pvt. Ltd., while Purva Sharegistry (India) Pvt. Ltd. acts as the registrar. Hem Finlease Pvt. Ltd. serves as the market maker and syndicate member. Historical capital actions include bonus issues of 2 for 1 in March 2016 and 9 for 1 in August 2025.
Financial Health and Earnings Consistency
A look at the consolidated numbers reveals steady top-line expansion interrupted by bottom-line swings. Total income and net profit stood at Rs. 184.81 crore and Rs. 32.10 crore in FY23, moving to Rs. 206.45 crore and Rs. 34.44 crore in FY24. In FY25, total income grew to Rs. 322.58 crore, but net profit slipped to Rs. 28.13 crore following an extraordinary item of Rs. 16.97 crore. For the nine-month period ended December 31, 2025, the firm posted a net profit of Rs. 38.69 crore on a total income of Rs. 236.50 crore.
This earnings spike right ahead of the IPO launch raises questions about long-term sustainability. Furthermore, balance sheet indicators show contingent liabilities of Rs. 61.64 crore and total borrowings of Rs. 242.57 crore as of December 31, 2025. Over the last two fiscal years, the company reported an average EPS of Rs. 25.00 and an average return on net worth of 23.17%. Profit-after-tax margins moved from 17.56% in FY23 to 16.92% in FY24, dropping to 8.97% in FY25 before recovering to 16.65% in the first nine months of FY26.
Valuation and Market Perspective
The issue is priced at a price-to-book value of 2.44 based on a net asset value of Rs. 140.81 per share as of December 31, 2025. If we annualize or attribute the strong nine-month FY26 earnings to the fully diluted post-IPO equity, the asking price translates to a price-to-earnings ratio of 15.51. Based on FY25 earnings, the P/E climbs to 28.44. The offer document lists no direct peer companies for comparison, leaving investors to judge the pricing purely on internal metrics.
The joint lead managers hold a track record of handling 79 issues over the past three years, with 8 of those closing below their issue price on their first day of trading. Given the sharp spike in pre-IPO earnings and heavy borrowings, the pricing looks full. The offering suits well-informed investors willing to lock away capital for a long horizon rather than those seeking quick listing gains.
Frequently Asked Questions
The company develops, manufactures, and markets medical reagents, point-of-care devices, consumables, and diagnostic equipment for healthcare needs.
The IPO aims to mobilize Rs. 214.48 crore at the upper price band through the issuance of 6,253,200 equity shares.
The price band is set between Rs. 326 and Rs. 343 per share, with a minimum application size of 800 shares.
The company intends to use Rs. 93.50 crore for working capital, Rs. 90.00 crore for debt repayment or prepayment, and the remainder for general corporate purposes.
The shares will be listed on the NSE SME Emerge platform.
The issue is jointly lead managed by Hem Securities Ltd. and Share India Capital Services Pvt. Ltd.
The company's overall borrowings stood at Rs. 242.57 crore as of December 31, 2025.
